

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures): 35 Rate: 6.2 CNY per page

Editing Fee: <u>217</u> CNY

Figure count: ______ Figure handling time: ______ Min_Rate: 1 CNY per min

Editing Fee: 0 CNY

XML and PDF converting time: 60 min Rate: 1 CNY per min

Editing Fee: <u>60</u> CNY

Manuscript word count: 8090

Total Editing Fee: <u>277</u> CNY

Scientific Editor: Yu-Lu Chen

Date of signature: _____07/06/2023 ____(month/day/year)

| Item No. | | Comments |
|----------|--|----------|
| | Specific items for verification | Yes=[Y] |
| | | No= [N] |
| | General Information of the Manuscript | |
| | Name of journal: World Journal of Gastroenterology | |
| | Manuscript NO.: 85374 | |
| | Column: Observational Study | |
| 1 | Title: New objective scoring system to clinically assess fecal | |
| 1 | incontinence | [Y] |
| | Authors: Pankaj Garg, Iwona Sudol-Szopinska, Małgorzata | |
| | Kolodziejczak, Kaushik Bhattacharya and Gurleen Kaur | |
| | Reviewer code: 06313495, and 06144658 | |
| | First decision: 2023-06-07 09:40 | |
| 2 | Editorial Office's Comments | [Y] |



Baishideng Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

Science Editor: The manuscript has been peer-reviewed, and it's ready for the first decision. Company Editor-in-Chief: I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastroenterology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Please authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content. Before final acceptance, when revising the manuscript, the author must supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply a new tool, the Reference Citation Analysis (RCA). RCA is an artificial intelligence technology-based open multidisciplinary citation analysis database. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further



| | improve an article under preparation/peer-review/revision. Please | |
|---|---|-----|
| | visit our RCA database for more information at: | |
| | https://www.referencecitationanalysis.com/. | |
| 3 | The fixed headings are copied. | [Y] |
| | The title concisely summarizes the main topic of the study and is | |
| | not too long (no more than 18 words). Words such as 'exploration', | |
| 4 | 'research', 'analysis', 'observation', and 'investigation' are avoided. | [Y] |
| | The title does not start with 'The' and does not include any Arabic | |
| | numbers or uncommon abbreviations. | |
| 5 | A short running title is provided (no more than 6 words). | [Y] |
| | The authors' full family (sur)names and full/abbreviated first | |
| 6 | names are listed on the title page and are consistent with those | [Y] |
| | listed in the signed BPG Copyright License Agreement form. | |
| | The 'Author contributions' passage describes the specific | |
| | contribution(s) made by each author. The author's names are listed | |
| | in the following format: full family (sur)name followed by | |
| | abbreviated first and middles names. | |
| | e.g., "Wang CL and Liang L contributed equally to this work; Wang | |
| 7 | CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the | [Y] |
| | research study; Wang CL, Zou CC, Hong F and Wu XM performed | |
| | the research; Xue JZ and Lu JR contributed new reagents and | |
| | analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and | |
| | Wang CL, Liang L and Fu JF wrote the manuscript. All authors | |
| | have read and approve the final manuscript." | |
| | The 'Supported by' statement describes the source(s) of financial | |
| 8 | support and includes the corresponding identification number(s) | [N] |
| | and program ID(s) if available, and contains no spelling errors. | |
| | | |



| 9 | The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (<i>e.g.</i> , MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors. | [Y] |
|----|--|------|
| 10 | The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors. | [Y] |
| 11 | The Abstract section is formatted according to the article-specific style (structured <i>vs</i> unstructured) and word count thresholds, as follows: <u>Commentary, Frontier, Diagnostic Advances, Medical Ethics,</u> <u>Minireview, Review, Therapeutics Advances, and Topic Highlight</u> : Non-structured abstract that is no less than 200 words. <u>Field of Vision, Case Report and Letter to the Editor</u> : Non-structured abstract that is no less than 150 words. <u>Research articles</u> : Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words). | [Y] |
| 12 | The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon. | [Y] |
| 13 | The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM, | [Y] |



| | 1 | |
|----|---|-----|
| | Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes | |
| | mellitus increases the risk of gastric cancer: A meta-analysis. World J | |
| | Gastroenterol 2019; In press | |
| | The 'Core tip' provides a summary (less than 100 words) of the | |
| 14 | study that outlines the most innovative and important arguments | |
| 14 | and core contents of the paper and will serve to effectively attract | [Y] |
| | readers. | |
| | The 'INTRODUCTION' section clearly describes the relevant | |
| | background information for the study. Only the most relevant and | |
| | current (within the past 5 years) literature is cited, with the | |
| | exception of rare instances of seminal literature citations. All | |
| | technical terms and/or abbreviations are explained and/or defined, | |
| 45 | with the full name of abbreviations given upon first appearance in | |
| 15 | the text and the abbreviation presented in parentheses [i.e., | [Y] |
| | "computed tomography (CT)"]. First-person pronouns (e.g., 'I', | |
| | 'we') are used appropriately to clearly indicate the work performed | |
| | by the author(s). When weaknesses of previous studies are | |
| | described in the text to highlight the innovations related to the | |
| | current study, the information is presented carefully. | |
| | The 'MATERIALS AND METHODS' section clearly and accurately | |
| 10 | describes all materials and methods used to obtain the data | |
| 16 | presented in the article and is adequate for a reader to repeat the | [Y] |
| | study. | |
| | The 'RESULTS' section concisely describes the observational and | |
| | experimental results. Representative data and data that have | |
| | scientific significance are emphasized. Data is presented in either | |
| 17 | the text, a table or figure (<i>i.e.</i> , chart, diagram, graph or image), but is | [Y] |
| | not repeated among each. Information presented in the tables and | |
| | figures clearly describes the trends, meaning, and inferences. | |
| | Results described in textual form are accurate, concise and clear. | |
| | | |



| 18 | Statistical symbols are accurate. Statistical significance is expressed | |
|----|---|-----|
| | as ${}^{a}P < 0.05$, ${}^{b}P < 0.01$ ($P > 0.05$ usually does not need to be denoted). | |
| | If there are other series of <i>P</i> values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used, | [Y] |
| | and a third series of <i>P</i> values is expressed as ${}^{e}P < 0.05$ and ${}^{f}P < 0.01$. | |
| | Statistical data is expressed as mean \pm SD or mean \pm SE. | |
| | The 'DISCUSSION' section (1) describes the main purpose and | |
| | hypothesis of the study; (2) summarizes the most important results; | |
| | (3) illustrates and explains the results (but does not simply repeat | |
| 10 | the data) and draws conclusions or inferences based on the results; | |
| 19 | (4) points out the limitations of the study and their impact on the | [Y] |
| | results, as well as proposes further advice on future research | |
| | topic(s) or direction(s); and (5) describes the theoretical significance | |
| | and practical value of the findings. | |
| | The 'ACKNOWLEDGEMENTS' section expresses gratitude to any | |
| | individuals or organizations for technical support (<i>i.e.</i> , providing | |
| | instrumentation, equipment or experimental materials, and/or | [Y] |
| 20 | assistance in experimental work), non-technical services (<i>i.e.</i> , useful | |
| | inspiration, suggestions, guidance, or review), and/or any other | |
| | auxiliary work. | |
| | The 'ARTICLE HIGHLIGHTS' section provides comments for | |
| 21 | original articles in accordance with the specified format. | [Y] |
| | The 'REFERENCES' section lists the references in the Vancouver | |
| | style. This style uses Arabic numeral in-text citations based on the | |
| | order of the first appearance of a source in the text. For citations | |
| 22 | where the author's name is indicated in the text, a superscript | [Y] |
| | number should be placed following the name (<i>i.e.</i> , "Pang <i>et al</i> "). For | |
| | citations where no author is indicated, a superscript number should | |
| | be placed at the end of the sentence. Respective examples are: "Ma ^[1] | |
| | reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high | |
| | sensitivity ^[6,9] ." No superscript numbers are used when the | |
| | | |



| | reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]). | |
|----|---|-----|
| 23 | Journal references have been verified to ensure that there are no duplicate references and that the PMID numbers are correct. For references not yet included in PubMed: the name of Chinese journals is spelled out using Chinese Pinyin, with the first letter of each word capitalized (<i>e.g., Shijie Huaren Xiaohua Zazhi</i>); the name of journals in other languages are listed according to indexing information retrieved from Google. Book references are presented with all the information relevant to the electronic version. | [Y] |
| 24 | The number of cited references is appropriate for the article type, as follows: <u>Commentary:</u> no less than 50; <u>Review:</u> no less than 100; <u>Article:</u> no less than 30/26; <u>Case Report and Letter to the Editor:</u> no less than 1. | [Y] |
| 25 | The ethics-related statements are provided in accordance with the manuscript type (<i>e.g.</i> , Manuscript NoInstitutional review board statement, Manuscript NoAnimal care and use statement, <i>etc.</i>). | [Y] |
| 26 | The names of the peer reviewers and the scientific editor are present at the end of the paper (<i>e.g.</i> , P-Reviewer: Hugot D S-Editor: Wang JL). | [Y] |



| 27The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (e.g., +, -, ×, *, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; F:[Y]28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Neeview).[Y]31The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoClinical trial registration sta | | | |
|--|----|--|-------|
| 27tables (e.g., +, -, ×, *, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastrifis tissue before and after treatment. A:, B, C, D, E, F[Y]28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistic statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | The order and numerical labeling of tables and figures is consistent | |
| 27 footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:, B:, C, D:, E:, F: [Y] 28 Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. [Y] 29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript. [Y] 30 The revised manuscript. [Y] 31 The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review(s)). [Y] 31 The response letter is provided (file name: Manuscript NoAnswering reviewers). [Y] 32 The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoBiostatistics statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | with their appearance and presentation in the text. Symbols in | |
| 27 consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: [Y] 28 Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. [Y] 29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript. [Y] 30 The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). [Y] 31 The letter of peer-reviewers' comments is provided (file name: Manuscript NoReview; e.g., 870-Answering reviewers). [Y] 32 The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form [Y] | | tables (<i>e.g.</i> , +, -, \times , \div , *) correctly correspond to the definitions in the | |
| consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | 27 | footnotes. Only one legend is provided for each multi-panel figure | [Y] |
| Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | _/ | consisting of color graphs, black and white graphs, or line graphs | [*] |
| treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | that depicts data of the same theme. For example: Figure 1 | |
| 28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | Pathological changes in atrophic gastritis tissue before and after | |
| 28graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | treatment. A:; B:; C:; D:; E:; F: | |
| 28 graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. 29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. [Y] 30 The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. [Y] 31 The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). [Y] 31 The letter of peer-reviewers' comments is provided (file name: Manuscript NoReview; e.g., 870-Review(s)). [Y] 31 The response letter is provided (file name: Manuscript NoAnswering reviewers). [Y] 32 The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | Split pictures include flow charts, line graphs, histograms, and | |
| 29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | 28 | graphs including text. Unsplit pictures include meta-analysis | [Y] |
| 29In the per-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | diagrams, PCR amplification curves, and survival curves. | |
| according to the peer-reviewers' comments.Image: the formula of the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).Image: The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).Image: The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).Image: The response letter is provided (file name: Manuscript NoAnswering reviewers).Image: The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | 20 | The author(s) highlighted the changes made to the manuscript | |
| 30[Y]the changes made to the manuscript.[Y]The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers).[Y]31The response letter is provided (file name: Manuscript NoAnswering reviewers); e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | 29 | according to the peer-reviewers' comments. | [I] |
| the changes made to the manuscript.The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoColflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form | 20 | The responses to the peer-reviewers' comments are consistent with | |
| NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | 30 | the changes made to the manuscript. | [ĭ] |
| 31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | The revised manuscript is provided (file name: Manuscript | |
| Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | NoReview; e.g., 870- Review). | |
| Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form | 21 | The letter of peer-reviewers' comments is provided (file name: | |
| NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial | 51 | Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). | |
| The related ethics and relevant documents are provided, such as (1)Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript32NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | The response letter is provided (file name: Manuscript | |
| Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers). | |
| approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | 32 | The related ethics and relevant documents are provided, such as (1) | |
| form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | Approved grant application form(s) or funding agency copy of any | |
| 32 NoBiostatistics statement); (3) Conflict-of-interest statement (file [Y] name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | approval document(s) (file name: Manuscript NoGrant application | |
| name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | form(s)); (2) Biostatistics review certificate (file name: Manuscript | |
| trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form | | NoBiostatistics statement); (3) Conflict-of-interest statement (file | [Y] |
| registration statement); (5) Institutional review board approval form | | name: Manuscript NoConflict-of-interest statement); (4) Clinical | |
| | | trial registration statement (file name: Manuscript NoClinical trial | |
| or document (file name: Manuscript NoInstitutional review board | | registration statement); (5) Institutional review board approval form | |
| | | or document (file name: Manuscript NoInstitutional review board | |



| | enterterment) (() Teatitutional entities 1 and 1 1 | |
|----|--|-----|
| | statement); (6) Institutional animal care and use committee | |
| | approval form or document (file name: Manuscript | |
| | NoInstitutional animal care and use committee statement), and (7) | |
| | Signed informed consent form(s) or document(s) (file name: | |
| | Manuscript NoInformed consent statement). | |
| | All authors signed the BPG Copyright license agreement form (file | |
| 33 | name: Manuscript NoCopyright license agreement; e.g., | [Y] |
| | 870-Copyright license agreement). | |
| | The language certificate provided by authors who are non-native | |
| 34 | speakers of English meets the BPG requirements (file name: | [Y] |
| | Manuscript NoLanguage certificate; <i>e.g.</i> , 870-Language certificate). | |
| | The photos licensed in the Agreement for Use of Personal Photos | |
| 25 | are consistent with those in the paper (file name: Manuscript | |
| 35 | NoAgreement for use of personal photos; e.g., 870-Agreement for | [N] |
| | use of personal photos). | |
| | This document (Checklist of Responsibilities for Scientific Editors) | [Y] |
| 36 | has been saved under the file name: manuscript NoScientific | |
| | editor work list (e.g., 870-Scientific editor work list). | |
| | A CrossCheck investigation (an effective tool for detecting unoriginal | |
| | content, enabling our editors to preserve the journal's integrity and | |
| | the authors' copyright) has been performed for the manuscript via | |
| | the website: http://www.ithenticate.com/. The results document | |
| | contains the following information for the manuscript: "Name of | |
| 37 | journal", "Manuscript No.", "Columns", "Title" and "Author list". | [Y] |
| | The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at | |
| | 1440 \times 680 pixel resolution. The PDF of the <i>CrossCheck</i> results has | |
| | been saved under the file name: manuscript No CrossCheck report | |
| | (e.g., 870-CrossCheck report). The Google searches have also been | |
| | performed to further ensure publication of original content. | |
| 38 | The text of the manuscript is typed in Book Antiqua font, 12 pt, with | [Y] |



| | 1.5 line spacing. | |
|--|--|--|
| Responsibilities of scientific editors | The primary responsibilities of our scientific editors include carefully checking the entire manuscript and all accompanying materials for: (1) errors in spelling, grammar, punctuation and wording; (2) suitability of tables, figures, figure data and legends; (3) accurate and appropriate presentation of symbols (<i>e.g.</i> +, -, ×, ÷, %, *) in tables and figures; and (4) complete and comprehensive revision of the manuscript | |
| Publication process | according to the reviewers' comments.Manuscript reception and registration→Initial review by scientific editor→Peerreview→End of peer review→First round of meeting evaluation→To beaccepted→Revision by the author(s)→Second round of meeting evaluation→To beaccepted/revised/rejected→Final review by the Editor-in-Chief (final qualitycontrol for academic content and language quality)→Final acceptance and chargingof publication fee→Language editing→Production→Proofreading by scientificeditor→Proofreading by deputy editor→Final review by Editor-in-Chief→Releaseof online open-access papers in electronic form on the BPG website→Release ofonline papers on PubMed Central→Delivery of high-quality PDF reprints to theauthor(s)→End of the publication process. | |